Sai Life Sciences Limited (BOM:544306)
India
· Delayed Price · Currency is INR 875.50
+8.70 (1.00%)
At close: Dec 5, 2025
Sai Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 20,532 | 16,946 | 14,652 | 12,171 | 8,696 | 7,599 |
| Revenue Growth (YoY) | 37.05% | 15.66% | 20.38% | 39.97% | 14.44% | - |
| Cost of Revenue | 6,171 | 5,131 | 4,845 | 4,667 | 3,092 | 2,451 |
| Gross Profit | 14,360 | 11,814 | 9,807 | 7,505 | 5,603 | 5,147 |
| Selling, General & Admin | 6,147 | 5,563 | 5,000 | 4,235 | 3,154 | 2,325 |
| Other Operating Expenses | 2,734 | 2,156 | 1,828 | 1,546 | 1,229 | 1,157 |
| Operating Expenses | 10,375 | 9,108 | 8,085 | 6,844 | 5,292 | 4,280 |
| Operating Income | 3,986 | 2,706 | 1,722 | 660.66 | 311.18 | 867.87 |
| Interest Expense | -557.29 | -761.64 | -859.11 | -770.57 | -495.71 | -303.23 |
| Interest & Investment Income | 175.65 | 175.65 | 135.97 | 106.64 | 70.5 | 82.75 |
| Currency Exchange Gain (Loss) | 190.76 | 190.76 | 146.26 | 173.02 | 97.84 | 158.35 |
| Other Non Operating Income (Expenses) | 73.02 | 1.38 | 8.59 | - | - | - |
| EBT Excluding Unusual Items | 3,868 | 2,312 | 1,154 | 169.75 | -16.19 | 805.73 |
| Gain (Loss) on Sale of Assets | -18.11 | -18.11 | 0.1 | -5.67 | 113.14 | -18.33 |
| Asset Writedown | -17.2 | -17.2 | -61.86 | - | - | - |
| Other Unusual Items | - | - | - | - | - | 31.79 |
| Pretax Income | 3,832 | 2,277 | 1,092 | 164.08 | 96.95 | 819.19 |
| Income Tax Expense | 968.25 | 575.71 | 264.25 | 64.19 | 34.69 | 208.18 |
| Net Income | 2,864 | 1,701 | 828.09 | 99.89 | 62.26 | 611.01 |
| Net Income to Common | 2,864 | 1,701 | 828.09 | 99.89 | 62.26 | 611.01 |
| Net Income Growth | 131.46% | 105.45% | 729.00% | 60.44% | -89.81% | - |
| Shares Outstanding (Basic) | 204 | 193 | 181 | 181 | 180 | 169 |
| Shares Outstanding (Diluted) | 210 | 198 | 183 | 182 | 182 | 172 |
| Shares Change (YoY) | 13.02% | 8.04% | 0.27% | 0.46% | 5.32% | - |
| EPS (Basic) | 14.06 | 8.83 | 4.57 | 0.55 | 0.35 | 3.61 |
| EPS (Diluted) | 13.64 | 8.61 | 4.53 | 0.55 | 0.34 | 3.54 |
| EPS Growth | 104.74% | 90.07% | 723.64% | 61.77% | -90.41% | - |
| Free Cash Flow | -1,978 | -552.35 | 813.97 | 1,063 | -1,020 | -2,985 |
| Free Cash Flow Per Share | -9.42 | -2.79 | 4.45 | 5.83 | -5.62 | -17.31 |
| Gross Margin | 69.94% | 69.72% | 66.93% | 61.66% | 64.44% | 67.74% |
| Operating Margin | 19.41% | 15.97% | 11.76% | 5.43% | 3.58% | 11.42% |
| Profit Margin | 13.95% | 10.04% | 5.65% | 0.82% | 0.72% | 8.04% |
| Free Cash Flow Margin | -9.63% | -3.26% | 5.56% | 8.74% | -11.73% | -39.28% |
| EBITDA | 4,980 | 3,596 | 2,454 | 1,261 | 916.14 | 1,346 |
| EBITDA Margin | 24.25% | 21.22% | 16.75% | 10.36% | 10.54% | 17.71% |
| D&A For EBITDA | 994.42 | 889.62 | 731.35 | 600.8 | 604.96 | 478.29 |
| EBIT | 3,986 | 2,706 | 1,722 | 660.66 | 311.18 | 867.87 |
| EBIT Margin | 19.41% | 15.97% | 11.76% | 5.43% | 3.58% | 11.42% |
| Effective Tax Rate | 25.26% | 25.28% | 24.19% | 39.12% | 35.78% | 25.41% |
| Revenue as Reported | 20,971 | 17,313 | 14,943 | 12,451 | 8,977 | 7,872 |
| Advertising Expenses | - | 50.14 | 30.45 | 11.14 | 51.05 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.